XM không cung cấp dịch vụ cho cư dân của Mỹ.
G
G

GSK


Tin tức

Arkema, Flatexdegiro, Mediobanca

EUROPE RESEARCH ROUNDUP-Arkema, Flatexdegiro, Mediobanca Oct 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Flatexdegiro and Mediobanca, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : Berenberg raises to buy from hold * Flatexdegiro AG FTKn.DE : Goldman Sachs raises to buy from neutral * Mediobanca MDBI.MI : Deutsche Bank raises to hold from sell * Orsted ORSTED.CO : Deutsche Bank cuts to hold from buy * Syensqo NV SYENS.
A
A
A
A
A
B
B
B
B
B
C
C
C
C
D
E
G
L
M
M
M
N
O
P
R
S
S
S
U
U
V
W
A
D
S
W

GSK plc reports results for the quarter ended in January 1 - Earnings Summary

GSK plc reports results for the quarter ended in January 1 - Earnings Summary GSK plc GSK.N reported quarterly adjusted earnings of $1.29​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of $1.28. The mean expectation of two analysts for the quarter was for earnings of $1.24 per share.
G

GSK CEO, on Catalent Takeover, Says Not Concerned About GSK's Manufacturing Capacity Moving Forward

BRIEF-GSK CEO, on Catalent Takeover, Says Not Concerned About GSK's Manufacturing Capacity Moving Forward Oct 30 (Reuters) - GSK plc GSK.L : GSK CEO WHEN ASKED ABOUT CATALENT TAKEOVER: NOT CONCERNED ABOUT GSK'S MANUFACTURING CAPACITY MOVING FORWARD, NO COMMENT ON DEAL -MEDIA CALL Further company coverage: GSK.L
G

GSK falls on slashing annual vaccines forecast

BUZZ-GSK falls on slashing annual vaccines forecast ** Shares in GSK GSK.L down as much as 3.5% at 1400p, lowest level since December 2023 ** Stock among top losers on FTSE 100 .FTSE index ** British drugmaker cuts 2024 vaccine sales forecast hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines ** Now sees FY vaccine s
G
U

UK Stocks-Factors to watch on Oct. 30

UPDATE 1-UK Stocks-Factors to watch on Oct. 30 Adds new items, updates futures Oct 30 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Wednesday, with futures FFIc1 down 0.6%. * GSK: GSK GSK.L lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.
B
G
G
N
S
A

GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand

UPDATE 4-GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Adds CEO comment from media call in paragraph 7, updates shares in bullet, paragraph 1 and final paragraph, adds context in paragraph 11 By Yadarisa Shabong and Maggie Fick Oct 30 (Reuters) - GSK GSK.L on Wednesday said its vaccine sa
G
N

GSK Says Q3 Shingrix Sales Down 7%, Arexvy Down 72%

BRIEF-GSK Says Q3 Shingrix Sales Down 7%, Arexvy Down 72% Oct 30 (Reuters) - GSK plc GSK.L : GSK PLC - 3RD QUARTER RESULTS GSK - CONFIRMS ITS FULL-YEAR SALES, CORE PROFIT AND EPS GUIDANCE AT CONSTANT EXCHANGE RATES (CER) GSK Q3 SALES SHINGRIX -7% AND AREXVY -72% GSK: 2024 GUIDANCE CONFIRMED GSK - EXPECTS TO DECLARE A DIVIDEND OF 60P PER SHARE FOR F
G

GSK lowers 2024 vaccine sales forecast

GSK lowers 2024 vaccine sales forecast Oct 30 (Reuters) - GSK GSK.L lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines. The British drugmaker expects 2024 vaccine sales to decrease by low-single digit percentage in turnover. It previously expected the business to grow by a low to mid-single digit percentage.
G

UK Stocks-Factors to watch on Oct. 30

UK Stocks-Factors to watch on Oct. 30 Oct 30 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Wednesday, with futures FFIc1 down 0.5%. * BUDGET: Britain's new finance minister Rachel Reeves will announce what may be the biggest tax hikes in three decades on Wednesday in a bid to fix the country's sagging public services, alongside billions of pounds of extra borrowing to overhaul the economy.
B
G
G
N
S
A
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Sweden's SKF, OpenAI, Colonial Pipeline Oct 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1933 GMT on Tuesday: ** Sweden's SKF said it sold its Hanover, Pennsylvania ring and seal operation, via subsidiary PCTI, to Carco PRP for 2.3 billion Swedish crowns ($215.98 million) as part of its strategy to exit the non-core aerospace sector.
B
C
G
H
N
V
A
A

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: GSK, Vodacom, CYVN Holdings Updates: Commonwealth Bank of Australia Oct 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Tuesday: ** GSK GSK.L said it would buy rights to develop and sell an experimental drug from China-based biotech firm Chimagen Biosciences in an up to $850 million deal, as the British pharmaceutical giant looks to expand its immunology pipeline.
C
G
H
V

GSK to buy rights to experimental drug from China's Chimagen in up to $850 mln deal

UPDATE 1-GSK to buy rights to experimental drug from China's Chimagen in up to $850 mln deal Adds details of deal in paragraphs 2-4,6 Oct 29 (Reuters) - GSK GSK.L said on Tuesday it would buy rights to develop and sell an experimental drug from China-based biotech firm Chimagen Biosciences in an up to $850 million deal, as the British pharmaceutical giant looks to expand its immunology pipeline.
G

GSK to buy experimental antibody from Chimagen in up to $850 mln deal

GSK to buy experimental antibody from Chimagen in up to $850 mln deal Oct 29 (Reuters) - GSK GSK.L said on Tuesday it would buy a clinical-stage experimental antibody from biotech firm Chimagen Biosciences in an up to $850 million deal, as the British pharmaceutical giant looks to expand its immunology pipeline. Reporting by Aby Jose Koilparambil i
G

GSK To Acquire CMG1A46 From Chimagen Biosciences For $300 Mln Upfront

BRIEF-GSK To Acquire CMG1A46 From Chimagen Biosciences For $300 Mln Upfront Oct 29 (Reuters) - GSK plc GSK.L : GSK ENTERS AGREEMENT TO ACQUIRE CMG1A46 FROM CHIMAGEN BIOSCIENCES TO EXPAND IMMUNOLOGY PIPELINE PROPOSED DEAL FOR $300 MILLION UPFRONT CHIMAGEN TO BE ELIGIBLE TO RECEIVE SUCCESS-BASED DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FOR CMG1A
G

India's GlaxoSmithKline Pharma posts higher Q2 profit on strong demand

India's GlaxoSmithKline Pharma posts higher Q2 profit on strong demand Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK GSK.L said its consolidated profit before tax rose to 3.44 billion rupees ($41 million) in the July-September quarter, from 2.99 billion rupees year ago.
A
G
P

India economic, corporate events on October 29

DIARY- India economic, corporate events on October 29 BENGALURU, Oct 29 (Reuters) - Diary of India economic, corporate events on October 29. ECONOMIC, CORPORATE .BSE500 EVENTS: Start Date Start Time RIC Company Name Event Name 29-Oct-2024 NTS VGUA.NS V Guard Industries Ltd Q2 2025 V Guard Industries Ltd Earnings Release 29-Oct-2024 NTS HITN.NS Hitachi Energy India Ltd Q2 2024 Hitachi Energy India Ltd Earnings Release 29-Oct-2024 NTS CNBK.NS Canara Bank Ltd Q2 2025 Canara Bank Ltd Earnings Releas
G

NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir

BRIEF-NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir Oct 28 (Reuters) - NIH: NIH: BOVINE H5N1 INFLUENZA FROM INFECTED WORKER TRANSMISSIBLE AND LETHAL IN ANIMAL MODELS NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS SUSCEPTIBLE TO ANTIVIRAL XOFLUZA AND NEURAMINIDASE INHIBITOR ZANAMIVIR NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS LESS S
G
R

Gsk PLC Says Single Dose Of Arexvy Shows Robust Immune Response In Adults 18-49

BRIEF-Gsk PLC Says Single Dose Of Arexvy Shows Robust Immune Response In Adults 18-49 Oct 24 (Reuters) - GSK plc GSK.L : GSK PLC - NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK GSK PLC - SINGLE DOSE OF AREXVY SHOWS ROBUST IMMUNE RESPONSE IN ADULTS 18-49 GSK PLC - TWO DOSES OF AREXVY IN IMMUNOCOMPROMISED ADULTS SHOW SIMILAR RESPONSE TO ONE DOSE
G

Shell setback upsets Nigeria's quest to lure investment

ANALYSIS-Shell setback upsets Nigeria's quest to lure investment Exxon Mobil decision was approved but after long wait Shell has not commented and regulator has not explained Some investors see positive change By MacDonald Dzirutwe LAGOS, Oct 23 (Reuters) - Nigeria's decision this week to block Shell's SHEL.L $2.4 billion sale of its onshore assets has sent a negative signal to investors the country urgently needs to strengthen its all-important oil sector, analysts said.
B
G

Northwestern sues Moderna for patent infringement over 19 vaccines

Northwestern sues Moderna for patent infringement over COVID-19 vaccines By Blake Brittain Oct 16 (Reuters) - Moderna MRNA.O was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger
G
P



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.